Products

From model readiness to recurring evidence.

Start with one model and one declared use. Assess the failure surface, attempt bounded hardening where a weakness is correctable, test the result on held-out real data, and preserve the failures as regression evidence.

Assess

Readiness and model diagnostics

Find measured weaknesses and determine what can be addressed. Available assessments stay bounded to one declared model use and evaluation scope.

01 / Available now

Synset Readiness Assessment

Buyer

Clinical AI teams preparing a model, dataset, or evaluation plan for a declared clinical use.

What Synset packages

A scoped review of model, data, coverage, calibration, subgroup, reproducibility, and technical evidence gaps, with a map of likely failure surfaces.

Differentiation

The assessment determines what is ready to test, which gaps may be correctable, what real evidence is still needed, and where the intended use should narrow.

declared-use review
data and split review
coverage map
calibration review
subgroup review
failure-surface map
correctability recommendation
Request readiness assessment

Available now

Documentation Model Assessment

A bounded assessment of unsupported assertions, omitted critical facts, contradictions, medication or lab mismatches, temporal errors, and sensitivity to documentation shifts.

Assess a documentation model

Available now

Coding / CDI Model Assessment

A bounded assessment of missed codes, unsupported codes, upcoding risk, diagnosis hallucination, and inconsistency between notes and structured evidence.

Assess a coding model

Available now

Risk Model Assessment

A bounded assessment of calibration, false negatives, subgroup behavior, missingness, drift, and risk coverage under controlled clinical conditions.

Assess a risk model
Harden

Attempt one bounded correction

Generate targeted training material for one supported weakness, then freeze the intervention before final evaluation.

02 / Bounded pilot

Synset Model Hardening Engagement

Buyer

Teams with a supported model, a declared use, a held-out evaluation path, and a gap that may be correctable.

What Synset packages

A bounded attempt to address one measured weakness using targeted synthetic training material and a frozen before-and-after evaluation.

Closed-loop hardening remains a pilot until held-out real-data results and external replication support broader model-improvement claims.

correctability decision
targeted hardening cohort
frozen intervention record
before-and-after evidence
Discuss a hardening engagement

Bounded pilot

Targeted Hardening Cohort

Checked synthetic clinical worlds targeted to one measured weakness and packaged for a frozen customer-run or Synset-supported hardening experiment.

Discuss a hardening cohort
Prove

Test whether the intervention worked

Compare frozen original and updated models on held-out real data, then preserve the observed failures as fixed tests.

03 / Design partner

Independent Hardening Study

Buyer

Investors, clinical AI vendors, regulated AI teams, health systems, strategic partners.

What Synset packages

A frozen design-partner intervention evaluated on held-out real data, with prespecified success criteria, no-regression gates, and a technical evidence package.

Differentiation

This is a design-partner evidence path, not a completed public proof asset unless a specific study is explicitly marked complete.

frozen study protocol
held-out evaluation reference
before-and-after results
no-regression review
residual-risk statement
Design an independent study

04 / Recurring expansion

Synset Regression Suite

Buyer

Vendors shipping frequent model updates, health-system AI governance groups, regulated software teams.

What Synset packages

A fixed, versioned set of checked scenarios and observed failures rerun after model, prompt, retrieval, threshold, workflow, or population changes.

frozen baseline suite
change-impact report
regression deltas
failure clusters
versioned evidence record
Build a regression suite
Maintain

Maintain evidence as the system changes

Enterprise design partners can rerun scoped regression evidence and evaluate models where customer-controlled real data already lives.

05 / Enterprise design partner

Synset Continuous Assurance

Buyer

Health-system AI governance committees, innovation teams, clinical informatics groups, academic medical centers.

What Synset packages

Recurring regression testing and evidence maintenance as models, prompts, retrieval, thresholds, workflows, or populations change within a declared evaluation scope.

Differentiation

Continuous assurance does not mean every future failure will be detected. It maintains scoped evidence against declared changes and known failure surfaces.

Discuss continuous assurance

06 / Enterprise design partner

Synset Local Validation Agent

Buyer

Health systems, hospital networks, model vendors with deployed enterprise clients, regulatory/governance platforms.

What Synset packages

An institution-local path for authorized evaluations, customer-controlled held-out comparison, and protected aggregate reporting.

Differentiation

Raw patient data can remain inside the customer environment. Customer-ready local deployment remains an enterprise design-partner path.

Discuss local validation
Supporting packages

Clinical-world material for development and QA.

Realistic synthetic clinical worlds are clinically coherent records, trajectories, evidence conditions, and scenarios. They can also support QA, integration, and controlled edge-case work without becoming the primary product category.

Available now

Synthetic Scenario and QA Packages

Checked patient scenarios, records, timelines, notes, and controlled variants for development, QA, demonstrations, benchmarks, and bounded assessments.

Request a scenario or QA package

Supporting package

FHIR / EHR Sandbox Blueprint

Clinically coherent, longitudinal, scenario-controlled test populations for integration tests, staging, demonstrations, and workflow simulation without PHI.

Request sandbox blueprint

Partner-driven

Rare-State Scenario Pack

Bounded scenario families for rare states, sparse evidence, unusual combinations, and clinically important edge conditions.

Discuss a rare-state pack
What a first hardening engagement requires
  • a defined model task and intended use
  • a reproducible inference path
  • a clear target or expected-output definition
  • available development data or model outputs
  • a customer-controlled held-out real evaluation set
  • prespecified success and no-regression criteria
  • an agreed customer-run or Synset-supported training arrangement

Synset does not accept every model or modality. Initial hardening pilots remain scoped to supported model classes and evidence conditions.

Roadmap and partner-driven directions

These are not current validated products unless a specific evidence artifact marks a use case as validated.

Imaging descriptors

Roadmap or partner-driven unless a specific evidence artifact marks a use case as validated.

Waveform descriptors

Roadmap or partner-driven support for workflow stress testing, not a validated current modality.

Clinical speech and dialogue simulation

Roadmap or partner-driven unless separately released with evidence and claim boundaries.

Life-sciences / RWE exploration

Exploration area for partner studies, not a public claim of broad real-world evidence validity.

Trial-feasibility exploration

Not synthetic control arms as a current product, and not a replacement for real-world validation.

Start with a readiness assessment.

Bring one model, one intended use, and one failure question. Synset will map the evidence and determine whether a bounded intervention is justified.

Available now

Readiness assessments and bounded model diagnostics.

Selected design partners

Bounded hardening pilots and customer-controlled local evaluation paths.